Insilico Medicine and SK Biopharmaceuticals Strike $2.5 B AI‑Driven CNS Drug Deal at BIO 2026
Insilico Medicine and SK Biopharmaceuticals announced a landmark research‑and‑development partnership at BIO 2026, committing up to $18 million in upfront payments and a potential $2.5 billion upside to co‑develop AI‑driven CNS drug candidates for neuroimmune disorders of the central nervous system (CNS). The collaboration pairs Insilico’s proprietary Pharma.AI platform with SK Biopharmaceuticals’ clinical development and commercialization expertise. Pharma.AI spans target…
